Hy, it is difficult to dispute any of your points
Post# of 36537
Where I disagree is that companies are so much farther ahead of NGIO. I'm not sure that they are all in the same lane as NGIO. Furthermore, it is clear that COVID is not going away anytime soon. In prior epidemics AE/NGIO did not have adequate time or resources to do proper testing with Ii-key. That is not the case this time, if what we have been told is true. These other companies, even those like PFE and MRNA, do not have Ii-key. Current vaccines are not going to be all things to all people.
It is your fourth paragraph that is most important. Are there updates? Has testing been done? Have the epitopes been identified? Is the money in the bank; in cyberspace, or merely in our hopes and dreams? Is uplisting a reality or just another empty promise? None of us can disagree that these are the most important questions.